Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
Open Access
- 29 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-9
- https://doi.org/10.1186/s12885-020-07436-6
Abstract
Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear. Through analysis of 2120 glioma patients from 5 public datasets, the relationships between C1RL expression and clinicopathological characteristics were evaluated. Furthermore, the C1RL-associated genes were screened, and Gene Ontology (GO) analysis was conducted to investigate biological process enrichment. In addition, tumour purity, leukocyte infiltration and overall survival were evaluated based on C1RL expression. We found that C1RL expression was upregulated in glioblastoma (GBM), especially mesenchymal GBM and primary GBM. Increased C1RL expression accompanied the IDH1-wt phenotype in both lower grade glioma (LGG) and GBM. C1RL- associated genes were mainly enriched in biological processes related to the immune response. C1RL expression was also correlated with reduced tumour purity and increased M2 macrophage infiltration. Higher C1RL expression predicted unfavourable survival in patients with glioma and therapeutic resistance in GBM. Our results imply that C1RL is involved in immunological activities and is an independent unfavourable prognostic biomarker in patients with glioma. C1RL is a potential clinical immunotherapeutic target for glioma treatment in the future.Keywords
Other Versions
Funding Information
- Beijing-Tianjin-Hebei Basic Research Cooperation Project (19JCZDJC64200)
- State Scholarship Fund from China Scholarship Council (201806940031)
This publication has 38 references indexed in Scilit:
- Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine modelNeuro-Oncology, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Proteomic characterization of serine hydrolase activity and composition in normal urineClinical Proteomics, 2013
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- Polymorphisms in complement system genes and risk of non-Hodgkin lymphomaEnvironmental and Molecular Mutagenesis, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- A novel human complement-related protein, C1r-like protease (C1r-LP), specifically cleaves pro-C1sBiochemical Journal, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like proteinProceedings of the National Academy of Sciences of the United States of America, 2004